ArticleTranslational pediatrics2024
Intravenous versus intramuscular route of administration of natural adrenocorticotropic hormone in infantile epileptic spasm syndrome.
Article in Translational pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Treatment history as early indicators of short-term response to ACTH therapy in infantile epileptic spasms syndrome: a propensity score matching analysis.Neurological research and practice · 2026Article
- Pharmacokinetics, Pharmacodynamics and Immunogenicity of AC02, a Novel Synthetic Derivate Peptide of Human Adrenocorticotropic Hormone for Infantile Spasms.Pharmaceutics · 2026Article
- Factors influencing adverse reactions to adrenocorticotropic hormone treatment in infantile epileptic spasm syndrome: a single-center retrospective study.Frontiers in pharmacology · 2026Article
- Short-Term Outcomes and Immunologic Mechanisms of Adrenocorticotropic Hormone in Infantile Epileptic Spasm Syndrome: A Multicenter Prospective Trial in Southern China.Neurology and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infantile epileptic spasm syndrome (ISS) is an age-dependent epileptic condition typically emerging within the first year of life, and adrenocorticotropic hormone (ACTH) has been established as a first-line therapeutic drug for the ISS since 1958. However, there is a notable variation in ACTH dosage practices worldwide, with intramuscular injection being common in some countries and intravenous drip preferred in others, including China. This study aimed to identify a preferable administration modality for ACTH-based utilization in treating ISS. Methods: A retrospective analysis was conducted on 221 ISS patients treated with ACTH via the two administration routes from January 2021 to December 2022. Clinical efficacy and adverse effects were assessed. Health economics were evaluated using a cost-effectiveness ratio, incorporating direct costs and a comprehensive effectiveness indicator. Results: Intramuscular injection demonstrated a higher effective rate (97.20%) compared to intravenous infusion (80.50%). Adverse effects such as upper respiratory tract infections and diarrhea were significantly less in the intramuscular group. The unit effectiveness cost was significantly lower for intramuscular injection (¥19.53) than for intravenous infusion (¥32.86). Conclusions: Although both routes of administration were successful in controlling spasms in patients, intramuscular injection of ACTH was deemed economically preferable due to its superior clinical efficacy, less adverse effects, and higher safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.